Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-06
1998-09-29
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514378, 514616, 514625, 514627, A61K 3142, A61K 3116
Patent
active
058146490
DESCRIPTION:
BRIEF SUMMARY
The present application has an effective international filing date of Oct. 4, 1995 as application Ser. No. PCT/JP95/02027 which designated the U.S. and entered the U.S. national phase on Apr. 14, 1997, under 35 USC 371, serial number not yet assigned.
FIELD OF THE INVENTION
This invention relates to a pharmaceutical composition for prophylaxis or treatment of Type I allergic diseases. More particularly, it relates to a pharmaceutical composition for prophylaxis or treatment of Type I allergic diseases which comprises as an active ingredient an anilide compound. Moreover, it relates to a use of an anilide compound for preparing a prophylactic or therapeutic agent for Type I allergic diseases. This invention is also concerned with a method for prophylaxis or treatment of Type I allergic diseases which comprises administering to a human being or a mammal an anilide compound.
BACKGROUND OF THE INVENTION
Allergic diseases are classified as Type I through Type IV. For their pathema, Type I may include pollinosis, asthma, atopic dermatitis and the like, Type II may include autoimmune hemolytic anemia, autoimmune thrombopenia and the like, Type III may include bacterial endocarditis, systemic lupus erythematosus and the like, Type IV may include tuberculosis, leishmaniasis, listeriosis and the like.
Mechanism of causing Type I allergic diseases is generally believed as discussed below. If allergens such as pollens, mites and the like are percutaneously or via the mucous membrane of respiratory organs or digestive organs introduced into the living body, immunoglobulin E (herein-after referred to as IgE) is produced within the body to these allergens and such IgE is bound to basophilic leukocytes or mast cells via a receptor. If the allergen is taken again in the state where IgE is bound to basophilic leukocytes or mast cells via a receptor, that is, under a sensitized condition, the allergen may be bound to the sensitized basophilic leuko-cytes or mast cells, from which may be released chemical mediators such as histamine, leukotriene, serotonin and the like. These released substances may induce a contracting action of smooth muscles of the respiratory tract and blood vessel, a vasopermeability-accelerating action, an edematization action of the mucosa in the respiratory tract and a mucus secretion-accelerating action, and thus Type I allergic symptoms such as bronchial asthma, dermal inflammation and the like would be translation-Supervised by Tomio Tada)!
As therapeutic agents for allergic diseases, there have been widely applied chemical mediator-release inhibitors such as Intal.RTM. (Fujisawa Pharmaceutical Co., Ltd.) (generic name: Disodium cromoglycate), chemical mediator-release inhibiting and antagonistic agents such as Celtect.RTM. (Kyowa Hakko Kogyo Co., Ltd.) (generic name: Oxatomide), Rizaben.RTM. (Kissei Pharmaceutical Co., Ltd.) (generic name: Tranilast) and synthetic adrenocortical hormones such as prednisolone. The mechanism of action of these drugs is that they inhibit the release of a chemical mediator capable of inducing allergic symptoms or they antagonize the chemical mediator thereby preventing the chemical mediator from binding to the corresponding receptor. Also, there may be utilized anti-inflammatory or immunosuppressive action of adrenocortical hormones. Problems involved in these drugs are that they are simply an agent usable for symptomatic treatment and should be taken whenever an allergen is introduced into the body to develop any symptoms, and that the allergic constitution itself which is characterized by a high blood IgE value is not treated at all.
DISCLOSURE OF THE INVENTION
It is an object of this invention to provide a pharmaceutical composition which can radically prevent or cure Type I allergic diseases by inhibiting the production of IgE which is the direct cause of Type I allergic diseases.
This invention is concerned with a pharmaceutical composition for prophylaxis or treatment of Type I allergic diseases which comprises as an active ingredient an anilide compoun
Amano Yukio
Mizushima Yuko
Ogata Kenji
Criares Theodore J.
Hoechst Pharmaceuticals & Chemicals K.K.
LandOfFree
Preventive and remedy for type 1 allergic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventive and remedy for type 1 allergic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventive and remedy for type 1 allergic diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686656